IgA nephropathy
Conditions
Interventions
None listed
Sponsors
Mogitate ENT Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients aged 18 years or older Diagnosed with chronic epipharyngitis and undergoing EAT as part of routine clinical care Patients with active IgA nephropathy, remission-phase IgA nephropathy, or non-renal disease controls Able to undergo blood tests, urinalysis, and endoscopic evaluation at baseline and after 12 EAT sessions Provided written informed consent for study participation
Exclusion criteria
Exclusion criteria: Patients with acute inflammatory diseases such as acute epipharyngitis, acute sinusitis, or acute tonsillitis Patients unable to undergo scheduled blood tests, urinalysis, or endoscopic evaluation Patients for whom EAT is medically inappropriate (e.g., severe gag reflex, bleeding tendency) Patients with severe systemic diseases (e.g., heart failure, liver failure, malignancy) that may interfere with study participation Pregnant women or those with possible pregnancy Any patient deemed unsuitable for participation by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in serum APRIL levels between baseline (before initiation of EAT) and after 12 EAT sessions | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in serum BAFF levels Change in serum Gd-IgA1 levels Change in serum uromodulin levels Change in urinalysis findings (dipstick and RBC/HPF) Change in serum creatinine and eGFR Change in endoscopic epipharyngeal findings (reference evaluation) | — |
Countries
Japan
Contacts
Public ContactManabu Mogitate
Mogitate Medical Corporation Mogitate ENT Clinic
Outcome results
None listed